AIM Logo

AIM ImmunoTech Inc. (AIM) 

AMEX
Market Cap
$15.43M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
222 of 790
Rank in Industry
133 of 440

Largest Insider Buys in Sector

AIM Stock Price History Chart

AIM Stock Performance

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic …

Insider Activity of AIM ImmunoTech Inc.

Over the last 12 months, insiders at AIM ImmunoTech Inc. have bought $152,677 and sold $0 worth of AIM ImmunoTech Inc. stock.

On average, over the past 5 years, insiders at AIM ImmunoTech Inc. have bought $108,295 and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Equels Thomas K (CEO & President) — $82,676. APPELROUTH STEWART (director) — $30,000. Rodino Peter W III (COO, Secretary, Gen. Counsel) — $25,000.

The last purchase of 5,000 shares for transaction amount of $1,515 was made by Equels Thomas K (CEO & President) on 2024‑09‑16.

List of Insider Buy and Sell Transactions, AIM ImmunoTech Inc.

2024-09-16PurchaseEquels Thomas KCEO & President
5,000
0.0089%
$0.30$1,515-3.87%
2024-09-13PurchaseEquels Thomas KCEO & President
20,000
0.0363%
$0.31$6,160-1.99%
2024-05-06PurchaseEquels Thomas KCEO & President
61,729
0.117%
$0.41$25,000-11.90%
2024-05-06PurchaseRodino Peter W IIICOO, Secretary, Gen. Counsel
30,865
0.0585%
$0.41$12,500-11.90%
2024-03-21PurchaseBRYAN NANCYdirector
38,462
0.0806%
$0.39$15,000+1.76%
2024-03-15PurchaseEquels Thomas KCEO & President
75,758
0.1551%
$0.33$25,000+17.81%
2024-03-15PurchaseAPPELROUTH STEWARTdirector
90,910
0.1861%
$0.33$30,000+17.81%
2024-03-15PurchaseRodino Peter W IIICOO, Secretary, Gen. Counsel
37,879
0.0776%
$0.33$12,500+17.81%
2023-11-27PurchaseEquels Thomas KCEO & President
33,861
0.0699%
$0.44$15,000-4.64%
2023-09-29PurchaseEquels Thomas KCEO & President
22,676
0.0452%
$0.44$10,000-6.80%
2023-08-25PurchaseEquels Thomas KCEO & President
8,222
0.0169%
$0.67$5,501-34.28%
2023-08-24PurchaseEquels Thomas KCEO & President
14,993
0.0308%
$0.67$10,000-35.27%
2023-07-17PurchaseEquels Thomas KCEO & President
16,950
0.0334%
$0.59$10,001-27.42%
2023-01-03PurchaseEquels Thomas KCEO & President
161,291
0.3212%
$0.31$50,000+54.75%
2023-01-03PurchaseAPPELROUTH STEWARTdirector
80,646
0.1606%
$0.31$25,000+54.75%
2023-01-03PurchaseRodino Peter W IIICOO, Secretary, Gen. Counsel
80,646
0.1606%
$0.31$25,000+54.75%
2021-07-16PurchaseEQUELS THOMAS K.CEO & President
15,625
0.0317%
$1.92$30,000-45.96%
2021-02-25PurchaseAPPELROUTH STEWARTdirector
10,638
0.0233%
$2.35$24,999-14.89%
2021-02-24PurchaseEQUELS THOMAS K.CEO & President
11,062
0.0233%
$2.26$25,000-14.89%
2020-12-17PurchaseEQUELS THOMAS K.CEO
14,535
0.042%
$1.72$25,000+9.63%

Insider Historical Profitability

<0.0001%
Equels Thomas KCEO & President
1493042
2.6131%
$0.27400<0.0001%
APPELROUTH STEWARTdirector
239765
0.4196%
$0.2780<0.0001%
Rodino Peter W IIICOO, Secretary, Gen. Counsel
212583
0.3721%
$0.2750<0.0001%
BRYAN NANCYdirector
38462
0.0673%
$0.2710
CARTER WILLIAM ACEO
1225585
2.145%
$0.27123

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$936,680.003.481.99M0%+$0<0.0001
BlackRock$328,915.001.22698,333-1.34%-$4,461.78<0.0001
Geode Capital Management$165,689.000.62351,6570%+$0<0.0001
Renaissance Technologies$104,000.000.39220,808+9.31%+$8,854.75<0.0001
State Street$81,532.000.3173,1030%+$0<0.0001